NCT00803569.

Trial name or title	Phase I study of ALVAC(2)‐NY‐ESO‐1(M)/TRICOM in patients with epithelial ovarian, fallopian tube, or primary peritoneal carcinoma whose tumours express NY‐ESO‐1 or LAGE‐1 antigen
Methods	Phase I
Participants	12 stage II‐IV women with ovarian cancer with complete response to primary or secondary (chemo)therapy
Interventions	SC ALVAC(2)‐NY‐ESO‐1(M)/TRICOM vaccine plus SC GM‐CSF
Outcomes	Safety Tumour responses Immune responses
Starting date	November 2008
Contact information
Notes	Completed 2011; no publication available